What is the definition of Calciphylaxis?

Calciphylaxis is a disease in which blood vessels (veins and arteries) become blocked by a build-up of calcium in the walls of the vessels, preventing blood from flowing to the skin or internal organs.  The lack of blood flow (ischemia) damages healthy tissue and causes it to die (necrosis).  The most obvious and frequent symptom of calciphylaxis is damage to the skin, as ulcers can develop and become infected easily.  Calciphylaxis can also affect fat tissue, internal organs, and skeletal muscle, causing infections, pain, and organ failure.  These symptoms are often irreversible, and many individuals with calciphylaxis may not survive more than a few months after they are diagnosed due to infection that spreads throughout the body (sepsis), or organ failure.  The exact cause of calciphylaxis is unknown.  Treatments may include medications to reduce pain, antibiotics to treat infections, and various approaches to preventing the development or worsening of this condition.

What are the alternative names for Calciphylaxis?

  • Idiopathic calciphylaxis
  • Condition: Calciphylaxis in Patient on Hemodialysis
  • Journal: BMJ case reports
  • Treatment Used: Sodium Thiosulfate
  • Number of Patients: 1
  • Published —
This case report describes an 81-year-old man on hemodialysis diagnosed with calciphylaxis (calcium accumulation).
  • Condition: Acute Cyanide Poisoning, Cisplatin Toxicities in Cancer Therapy, and Calciphylaxis in Dialysis Patients
  • Journal: International journal of molecular sciences
  • Treatment Used: Sodium Thiosulfate (STS)
  • Number of Patients: 0
  • Published —
This review discusses the use of sodium thiosulfate (STS) in the treatment of patients with acute cyanide poisoning, cisplatin toxicities in cancer therapy, and calciphylaxis (calcium deposits in small blood vessels) in dialysis patients.
Clinical Trial
  • Status: Recruiting
  • Participants: 300
  • Start Date: January 2017
Partners Calciphylaxis Biobank and Patient Registry
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 66
  • Start Date: February 12, 2020
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis